Dag Clement Johannessen

Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer

Chris Parker, Sten Nilsson, Daniel Heinrich et al. · New England Journal of Medicine · 2013 · 3.3K citations

Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study

Sten Nilsson, Lars Franzén, Christopher Parker et al. · The Lancet Oncology · 2007 · 491 citations

Bone-targeted Radium-223, Urology, Genitourinary Cancer +6

Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial

Oliver Sartor, Robert L. Coleman, Sten Nilsson et al. · The Lancet Oncology · 2014 · 485 citations

Urology, Oncology, Medicine +8

Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial

Peter Hoskin, Oliver Sartor, Joe M. O’Sullivan et al. · The Lancet Oncology · 2014 · 403 citations

Urology, Medicine, Pharmacology +7

Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study.

Dag Clement Johannessen, Terje Engan, E. Di Salle et al. · PubMed · 1997 · 193 citations

Breast Oncology, Gynecology, Pharmacotherapy +18